Health and Quality of Life Outcomes

Table 4 Correlations of changes in SF-36 BP, VT, and MCS scores with changes in DLQI and pruritus VAS scores at week 16

From: Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

	Placebo	Apremilast BID
		10 mg	20 mg	30 mg
SF-36 BP with DLQI	−0.45*	−0.32*	−0.52*	−0.35*
SF-36 BP with DLQI	P<0.001	P=0.002	P<0.001	P=0.001
SF-36 VT with DLQI	0.38*	−0.18	−0.33*	−0.23
SF-36 VT with DLQI	P<0.001	P=NS	P=0.003	P=0.040
SF-36 MCS with DLQI	−0.57*	−0.41*	−0.42*	−0.31*
SF-36 MCS with DLQI	P<0.001	P<0.001	P<0.001	P=0.004
SF-36 BP with pruritus VAS	−0.39*	−0.27	−0.43*	−0.30
SF-36 BP with pruritus VAS	P<0.001	P=0.013	P<0.001	P=0.005
SF-36 VT with pruritus VAS	−0.36*	0.01	−0.11	−0.23
SF-36 VT with pruritus VAS	P=0.001	P=NS	P=NS	P=0.034
SF-36 MCS with pruritus VAS	−0.35*	−0.21	−0.12	−0.35*
	P=0.001	P=NS	P=NS	P=0.001

*Moderate correlations (r>0.30 and ≤0.60).
BP, Bodily Pain; DLQI, Dermatology Life Quality Index; MCS, mental component summary; SF-36, Short-Form 36 Health Survey; VAS, visual analog scale; VT, Vitality.

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com